Nanjing Leads Biolabs Co.,Ltd

9887 · HKEX

Public Market Listing

9887HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Nanjing Leads Biolabs Co.,Ltd are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
PD-L1 + 4-1BB (CD137)Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 1/2
GPRC5D x CD3Multispecific antibody
Multiple Myeloma
Phase 1
BDCA2 (CLEC4C) / TACIProtein / enzyme therapeutic
Systemic Lupus Erythematosus

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
OpamtistomigPhase 1/2Advanced Solid Tumor
Est. primary completion 2026-12 · NCT05170958 · CT.gov ↗
What to watch
OpamtistomigPhase 2Advanced Solid Tumour
Est. primary completion 2026-12-24 · NCT06783647 · CT.gov ↗
What to watch
OpamtistomigPhase 1/2Advanced Neuroendocrine Carcinoma
Est. primary completion 2026-12-28 · NCT06157827 · CT.gov ↗
What to watch
2027 (4)
October 2027 (1)
OpamtistomigPhase 1/2Advanced Melanoma
Est. primary completion 2027-10-30 · NCT07099430 · CT.gov ↗
What to watch
December 2027 (3)
OpamtistomigPhase 1/2Ovarian Cancer
Est. primary completion 2027-12-25 · NCT07042802 · CT.gov ↗
What to watch
OpamtistomigPhase 2Advanced Solid Tumour
Est. primary completion 2027-12-26 · NCT07111546 · CT.gov ↗
What to watch
OpamtistomigPhase 1/2Triple Negative Breast Cancer
Est. primary completion 2027-12-31 · NCT07281976 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
OpamtistomigPhase 2Advanced Solid Tumour
Est. primary completion 2028-05-30 · NCT07390383 · CT.gov ↗
What to watch
December 2028 (1)
OpamtistomigPhase 2Advanced Solid Tumour
Est. primary completion 2028-12-26 · NCT07331155 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
LBL-034Phase 1/2Relapsed/Refractory Multiple Myeloma
Est. primary completion 2029-09-20 · NCT06049290 · CT.gov ↗
What to watch
2030 (2)
September 2030 (1)
OpamtistomigPhase 1/2Metastatic Colorectal Carcinoma
Est. primary completion 2030-09-04 · NCT07791758 · CT.gov ↗
What to watch
December 2030 (1)
OpamtistomigPhase 3Advanced Extrapulmonary Neuroendocrine Carcinoma
Est. primary completion 2030-12-22 · NCT07720193 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 July 2026Priority reviewOpamtistomigChina's CDE accepts the opamtistomig BLA for EP-NEC into priority review
CN, NMPA (CDE) · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q1—$8.0M$59M$10Mreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$26M—$10Mreport ↗

Nanjing Leads Biolabs Co.,Ltd reported revenue of $0M, R&D spend of $25.89M, and a net loss of $41.89M for fiscal year 2024.

Figures only: this period's report disclosed no narrative text